Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis

J Blum, DNJ Lockwood, L Visser, G Harms, MS Bailey… - International health, 2012 - Elsevier
This review addresses the question of whether the risk of developing mucosal leishmaniasis
(ML) warrants systemic treatment in all patients with New World cutaneous leishmaniasis …

Review of the clinical presentation, pathology, diagnosis, and treatment of leishmaniasis

BA Mathison, BT Bradley - Laboratory Medicine, 2023 - academic.oup.com
Leishmaniasis is a vector-borne infection caused by kinetoplastid protozoans in the genera
Leishmania and Endotrypanum. The disease occurs worldwide in the tropics and subtropics …

[HTML][HTML] Disseminated leishmaniasis: clinical, pathogenic, and therapeutic aspects

GU Machado, FV Prates, PRL Machado - Anais brasileiros de …, 2019 - SciELO Brasil
Disseminated leishmaniasis is a severe and emerging form of American tegumentary
leishmaniasis. Disseminated leishmaniasis is defined by the presence of more than 10 …

A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.

YA Skeiky, JA Guderian, DR Benson… - The Journal of …, 1995 - rupress.org
Leishmania braziliensis causes cutaneous and mucosal leishmaniasis in humans. Most
patients with cutaneous leishmaniasis heal spontaneously and may therefore have …

Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization.

KA Weigle, L Valderrama, AL Arias… - The American journal …, 1991 - europepmc.org
Leishmanin skin test (LST) antigens prepared from Leishmania braziliensis panamensis
were compared with respect to sensitivity, specificity, and side effects. Within the dose range …

Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous leishmaniasis

K Weigle, NG Saravia - Clinics in dermatology, 1996 - Elsevier
ACL is produced by a group of genetically related species, each of which has characteristic
manifestations and areas of endemnicity (Table 1) le3; however, none of the clinical …

[HTML][HTML] Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year …

L Jirmanus, MJ Glesby, LH Guimaraes… - The American journal …, 2012 - ncbi.nlm.nih.gov
Abstract The Health Post of Corte de Pedra is located in a region endemic for American
tegumentary leishmaniasis (ATL) in the Brazilian state of Bahia, and it treats 500–1,300 …

Toward a Novel Experimental Model of Infection To Study American Cutaneous Leishmaniasis Caused by Leishmania braziliensis

TR De Moura, FO Novais, F Oliveira… - Infection and …, 2005 - Am Soc Microbiol
Leishmania spp. cause a broad spectrum of diseases collectively known as leishmaniasis.
Leishmania braziliensis is the main etiological agent of American cutaneous leishmaniasis …

[HTML][HTML] The immunobiology of Leishmania braziliensis infection

CI de Oliveira, CI Brodskyn - Frontiers in immunology, 2012 - frontiersin.org
Leishmaniases are a group of diseases caused by protozoa of the genus Leishmania that
affect millions of people worldwide. These diseases are caused by distinct Leishmania …

[PDF][PDF] Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics.

LE Osorio, CM Castillo, MT Ochoa - The American journal of tropical …, 1998 - academia.edu
The Leishmaniases are a group of diseases whose clinical presentation is in part
determined by the infecting species. Until recently, mucosal leishmaniasis was attributed …